Betterlife Pharma Stock Fundamentals
| BETRF Stock | USD 0.07 0.01 14.62% |
BetterLife Pharma fundamentals help investors to digest information that contributes to BetterLife Pharma's financial success or failures. It also enables traders to predict the movement of BetterLife OTC Stock. The fundamental analysis module provides a way to measure BetterLife Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BetterLife Pharma otc stock.
BetterLife |
BetterLife Pharma OTC Stock Shares Outstanding Analysis
BetterLife Pharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current BetterLife Pharma Shares Outstanding | 90.1 M |
Most of BetterLife Pharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BetterLife Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, BetterLife Pharma has 90.1 M of shares currently outstending. This is 50.09% lower than that of the Healthcare sector and 15.68% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 84.24% higher than that of the company.
BetterLife Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BetterLife Pharma's current stock value. Our valuation model uses many indicators to compare BetterLife Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BetterLife Pharma competition to find correlations between indicators driving BetterLife Pharma's intrinsic value. More Info.BetterLife Pharma is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BetterLife Pharma's earnings, one of the primary drivers of an investment's value.BetterLife Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BetterLife Pharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of BetterLife Pharma could also be used in its relative valuation, which is a method of valuing BetterLife Pharma by comparing valuation metrics of similar companies.BetterLife Pharma is currently under evaluation in shares outstanding category among its peers.
BetterLife Fundamentals
| Return On Equity | -44.17 | |||
| Return On Asset | -4.05 | |||
| Current Valuation | 12.42 M | |||
| Shares Outstanding | 90.1 M | |||
| Shares Owned By Insiders | 8.41 % | |||
| Price To Book | 13.65 X | |||
| Gross Profit | (22.81 K) | |||
| EBITDA | (11.92 M) | |||
| Net Income | (12.16 M) | |||
| Cash And Equivalents | 14.41 K | |||
| Total Debt | 34.56 K | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (11.2 M) | |||
| Earnings Per Share | (0.12) X | |||
| Beta | 1.62 | |||
| Market Capitalization | 9.49 M | |||
| Total Asset | 1.16 M | |||
| Net Asset | 1.16 M |
About BetterLife Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BetterLife Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BetterLife Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BetterLife Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada. Betterlife Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in BetterLife OTC Stock
BetterLife Pharma financial ratios help investors to determine whether BetterLife OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BetterLife with respect to the benefits of owning BetterLife Pharma security.